Viropro, Inc. (VPRO)

[Penny Stocks 2.0]

We continue to be committed to securing partnership agreements with companies seeking to serve Asian and Latin American markets by manufacturing biosimilars in Malaysia. Because there are now multiple sources of manufacturing-ready clones for the major biologics which are either off patent or nearing the end of their patent protection, we do not believe that it is in our best interest to develop such clones for other parties. Instead, we will focus on making our facility available under contract to firms whose products are ready for late-stage clinical or commercial production. Some of those discussions are underway, and we believe that contract manufacturing services represent an important short-term source of revenue for Viropro. We also believe that we can secure sufficient capital for the refurbishment of the Penang facility on the basis of a signed agreement with a reputable manufacturing partner.